Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation

A case report

Xiang Tan, MD, Lei Dai, MD, Yongyong Wang, MD, Guanbiao Liang, MD, Nuo Yang, MD, Mingwu Chen, MD

Abstract

Rationale: Mesenchymal-to-epithelial transition (MET) exon 14 skipping mutation was a targetable alteration in nonsmall-cell lung cancer (NSCLC), and the MET inhibitor of crizotinib had the most efficacy among all the targeted drugs. Most of the cancer-related deaths are associated with metastasis. Circulating tumor cells (CTCs) have been a valuable biomarker in assessing metastasis. Recent experiences suggested that CTCs detection may help improve diagnosis and predict prognosis for patients with NSCLC. However, few literatures have reported the CTCs detection based on the (MET) exon 14 skipping, which are positive in NSCLC patients.

Patient concerns: The patient, a 69-year-old Chinese male, with a 50 years history of smoking. Because of the cough, the patient went to the hospital and found the upper right lung tumor and the right supraclavicular lymph node enlarged. He was worried that it was cancer.

Diagnoses: The patient was performed biopsy of the right clavicle lymph node metastasis on October 12 and sent the tissue specimen for pathological evaluation. Finally, the patient was diagnosed to be with a pT3N3Mx stage IIIC lung adenocarcinoma.

Interventions: The patient began to take orally crizotinib 250 mg twice a day for the medical therapy after lymph node biopsy. At the same time, the CTCs were detected to observe the prognosis of the patients.

Outcomes: Compared with the first CTCs result, the second test revealed a decrease in the amount of CTCs, while the mesenchymal CTCs have increased, indicating the possibility of distal metastasis.

Lessons: This is the first proof that CTCs can be quantitatively assayed by MET exon 14 skipping mutation, which demonstrates the clinical response to crizotinib. More cases should be reported and further evaluation for treatment options and prognosis evaluation is necessary.

Abbreviations: CT = computed tomography, CTCs = circulating tumor cells, EMT = epithelial-mesenchymal transition, HGF = hepatocyte growth factor, MRI = magnetic resonance imaging, TKIs = tyrosine kinase inhibitors.

Keywords: exon 14 skipping, crizotinib, circulating tumor cells (CTCs), lung adenocarcinoma, MET
1. Introduction

Nowadays, lung cancer is one of the leading causes for global cancer-related mortality in both men and women, resulting in over 1 million deaths each year, while among all of the types, adenocarcinoma is the commonest histological one. In the past 10 years, novel molecular targeted therapies were used by people for the treatment of lung adenocarcinomas. MET proto-oncogene has long been the focus of therapeutic target in lung cancer. MET has played an important part in cell proliferation, oncogenic capacity. Now, in 4% of lung adenocarcinoma cases, MET exon 14 skipping has been used to report. Preclinical systems support the use of MET tyrosine kinase inhibitors (TKIs) and crizotinib in MET exon 14 skipping, and off-label use of crizotinib has also accumulated its clinical experiences in these patients. Recently, several case reports have already been using the MET exon 14 skipping to demonstrate the clinical responses to crizotinib in lung adenocarcinomas.

Most cancer-related deaths are associated with metastasis. Metastasis is a multi-step process, while the blood stream is disseminated from primary tumors, and the CTCs will be present in the blood stream. CTCs need to go through a process of epithelial-mesenchymal transition (EMT), through the loss of epithelial cells’ characteristics and the acquisition of a mesenchymal phenotype, providing the cells with improved invasive potential for distal metastasis. Evidence accumulated has implicated that CTCs can be used as a biomarker in the noninvasive monitor of cancer metastasis and offer information to help instruct therapy selection. Because of their EMT characteristics and the acquisition of a mesenchymal CTCs, indicating metastasis, increase.

2. Case report

The patient is a 69-year-old Chinese male, with a 50 years history of smoking. A computed tomography (CT) scan of the patient’s chest on October 8, 2015, revealed a space-occupying mass measuring 13.2 × 8.8 × 9 cm in size with multiple lymph node metastases (Fig. 1). After further evaluation of the serum tumor markers, such as CEA, CA125, CA15-3, CA19-9, ferritin, CYFRA21–1, WBC, SCCA, NSE, AST, and ALT, malignant pulmonary tumor is indicated in the patient’s body. Then, physicians performed biopsy of the right clavicle lymph node metastasis on October 12 and sent the tissue specimen for pathological evaluation (data not shown). Finally, the patient was diagnosed to be with a pT3N3Mx stage IICClung adenocarcinoma.

In order to probe into the genomic profile of the tumor for targeted therapy, the tissue specimen of the patient’s right clavicle lymph node metastasis and the related blood sample were sent for next-generation sequencing panel analysis after the consent was obtained from the patient and his family members. We have checked all of the genomic alteration types from the patient, including base substitutions, insertions and deletions, copy number alterations, and rearrangements on over 390 genes, which are normally connected with cancers. The genomic profile of the tumor disclosed 3 somatic mutations, including c.3025–3028+5del mutation of MET (NM_000245.2) gene, c.599–1G>A mutation of PIK3R2 (NM_005027.3) gene, and Q38Kfs*6 mutation of TP53 (NM_000546.5) gene. The MET c.3025–3028+5del mutation would have the consequence of 9 nucleotides deletion around the 3’ splice donor site of MET exon 14, and result in exon 14 skipping (Fig. 2). MET exon 14 skipping would have the consequence of 9 nucleotides deletion around the 3’ splice donor site of MET exon 14, and result in exon 14 skipping (Fig. 2). MET exon 14 skipping would have the consequence of 9 nucleotides deletion around the 3’ splice donor site of MET exon 14, and result in exon 14 skipping (Fig. 2).
has proved its function in mitigating MET degradation; in the meanwhile, it leads to the increasing of MET protein expression. So, the patient began to take orally crizotinib 250mg twice a day for the medical therapy since November 4, which has been provided off-label but with insurance validation. After 4 weeks of treatment, the CT scan of the patient on December 2 showed significant reduction of both lung tumor and lymph node metastases. His lung tumor measured 7.3 \times 5.3 \times 7.6\text{ cm} in size, meeting RECIST partial response criteria (\text{\(-42.4\%\)}; Fig. 1). Also, during the crizotinib treatment, the patient accepted the treatment with good tolerability and only experienced grade 2 diarrhea.

At the same time, in order to develop noninvasive liquid biopsy for distal metastases monitoring, 10\text{ mL} of peripheral blood of the patient was collected on October 13 for CTCs test with the agreement of the patient and his family members. CTCs test disclosed the existence of 7 epithelial CTCs and 3 biophenotypic epithelial/mesenchymal CTCs (Fig. 3). On December 4, CTCs test was implemented again, and 8 CTCs in total were confirmed to be 2 biophenotypic epithelial/mesenchymal CTCs and 6 mesenchymal CTCs (Fig. 3). Compared with the first CTCs result, the second test revealed a decrease in the amount of CTCs, while the mesenchymal CTCs have increased, indicating the possibility of distal metastasis. What is more, brain magnetic resonance imaging (MRI) scan, which the patient took, disclosed the multiple lesions in cerebrum, brainstem, and both cerebellar hemispheres, implicating brain metastases and consistent with the CTCs results. So, in the end, that patient died of respiratory failure caused by brain metastases 2 months later.

3. Discussion

Current report not only supports the idea that MET exon 14 skipping in lung adenocarcinoma is the oncogene but also shows that clinical responses can be quickly observed with the usage of MET inhibitor crizotinib. Unlike most splice site mutations that lead to the loss of reading frame and protein truncation, MET exon 14 splice site mutations will lead to the constitutive activity of MET. Commensurately, MET exon 14 skipping has been found and reported in 4\% of lung adenocarcinomas, having the frequency as twice as that of MET amplification. Except above mentioned, MET exon 14 skipping has also been ascertained in the lung cancer of small cells,\textsuperscript{20}\& glioblastoma multiforme,\textsuperscript{21}\& and squamous cell head and neck cancers.\textsuperscript{22}\ These data have proved the role of MET exon 14 skipping in the driving and impulsing of tumorigenesis, and it has also confirmed a distinct group of patients who are likely to gain benefit from MET inhibitors, such as crizotinib. As there are no clinical experiments currently that focus on the MET exon 14 skipping cancer population, the amassing of clinical responses recorded in case reports is the only form of clinical evidence revealing the targetability of MET exon 14 skipping. In the short run, it may emerge that cancer diseases with MET exon 14 skipping involved in will profit by anti-MET targeted treatment.

Crizotinib is a small molecule inhibitor of ALK, MET, and ROS1 receptor tyrosine kinase, which is potent and selective ATP-positive. The lung adenocarcinoma patient with MET exon 14 skipping mutation in this case has shown rapid clinical response to crizotinib treatment. For the reason that crizotinib’s ability of penetrating the blood–brain barrier is quite lacked\textsuperscript{23,24}\ in the therapy of brain metastases, the function crizotinib can impose to the disease is very confined. That is why the patient in the case died for his brain metastases deteriorated despite the treatment’s effects to the lung tumor.

Besides MET exon 14 mutation, genomic profile of the tumor has disclosed 2 other somatic mutations, c.599–1G\rightarrow*A mutation of PIK3R2 and Q38Kfs*6 mutation of TP53. PIK3R2 gene encodes p85\textsubscript{β}, a managing subunit of PI3K that connects and stabilizes PTEN. c.599–1G\rightarrow*A mutation of PIK3R2 in this case is speculated to impair splicing, resulting in p85\textsubscript{β} mRNA degradation or protein abnormality, and the related results would hinder the interactions between p85 and PTEN; what is more, it would also promote PTEN degradation by ubiquitination. As a result, PIK3R2 mutation would lead to the activation of PI3K/AKT/mTOR signaling routes, which is included in cell growth, survival, proliferation, motility, and morphology; also, the preclinical study suggested that when the tumor cells are connected with PIK3R2 mutation, they would be sensitive to mTOR inhibitors.\textsuperscript{22}\ Tumor suppressor p53, which is produced by TP53 gene, will be either be lost or mutated in various malignancies.\textsuperscript{26}\ No medicine targeting TP53 have been ever approved, although it was used to reveal that TP53 mutation was quite responsive to Wee-1 inhibitor MK-1775,\textsuperscript{27,28}\ except that the clinical experiment NCT01357161, MK-1775, proved a preliminary response rate of 78.6\% (11/14) in p53-mutant ovarian cancer. Thus, mTOR inhibitor everolimus, Wee-1 inhibitor MK-1775, or the unity of several targeted drugs may be used as an alternative for patients who have multiple mutations.
As mentioned above, CTCs can be used as biomarkers for noninvasive monitor cancer distal metastasis and mesenchymal CTCs is most closely associated with distal metastasis. Therefore, using EMT markers to differentiate CTCs helps to identify more aggressive CTC subpopulation and provides useful evidence for distal metastasis. In this case report, the increased mesenchymal CTCs were consistent with brain MRI results, which indicate the brain metastasis.

In summary, MET exon 14 skipping mutation was a targetable alternative in NSCLC, and the MET inhibitor of crizotinib possesses the most efficacy among all the targeted drugs. As most of the cancer-related deaths are associated with metastasis, CTCs is a valuable biomarker in assessing metastasis. In this report, a patient case was analyzed and demonstrated to show that the one with MET exon 14 skipping mutation can respond to MET-directed targeted therapy, and CTCs can be used as biomarkers to noninvasive monitor cancer metastasis, as the patient did not appear to be unadaptable to the treatment. As far as we know, this is the first report developing noninvasive CTCs for distal metastases monitoring in a lung adenocarcinoma patient with MET exon 14 skipping mutation that demonstrated clinical response to crizotinib. However, for the reason that the patient finally died of the respiratory failure caused by brain metastases, it is critically important that we develop the mechanism for the identification of new subsets of patients who will be likely to benefit from the targeted therapy as well as the noninvasive liquid biopsy for monitoring distal metastases to improve cancer patient care. We still have a long way to go in exploring that.

References

[1] Cancer Genome Atlas Research Network. Comprehensivne molecular profiling of lung adenocarcinoma. Nature 2014;511:343–50.
[2] Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014;311:1998–2006.
[3] Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. J Clin Oncol 2013;31:1089–96.
[4] Scagliotti GV, Novello S, von Pawel J. The emerging role of MET/HER2 inhibitors in oncology. Cancer Treat Rev 2013;39:793–801.
[5] Krishnaswamy S, Kanteti R, Duke-Cohan JS, et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 2009;15:7114–23.
[6] Kong-Beiran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006;66:283–9.
[7] Peschard P, Park M. Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 2003;3:519–23.
[8] Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 2015;5:850–9.
[9] Waqar SN, Morgenstern D, Sehn J. MET mutation associated with responsiveness to crizotinib. J Thorac Oncol, 2015.;10:e29–31.
[10] Jenkins RW, Oxnard GR, Elkin S, et al. Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation. Clin Lung Cancer 2015;16:e101–4.
[11] Paik FK, Drilon A, Fan FD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 2015;5:842–9.
[12] Jorge SE, Schulman S, Freed JA, et al. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer 2015;90:569–74.
[13] Shea M, Huberman MS, Costa DB. Lazarus-type response to crizotinib in a patient with poor performance status and advanced MET exon 14 skipping mutation-positive lung adenocarcinoma. J Thorac Oncol 2016;11:e81–2.
[14] Mahjoubi L, Gazzah A, Besse B, et al. A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib. Invest New Drugs 2016;34:397–8.
[15] Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679–95.
[16] Kuzakiewicz M, Markiewicz A, Zacek AJ. Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology 2012;79:195–208.
[17] Hou JM, Krebs M, Ward T, et al. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol 2011;178:989–96.
[18] Wu S, Liu S, Liu Z, et al. Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS One 2015;10:e0123976.
[19] Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339:580–4.
[20] Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003;63:6272–81.
[21] Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061–8.
[22] Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:11.
[23] Kinoshiya H, Koga Y, Sakamoto A, et al. Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer. BMJ Case Rep 2013;2013:0230867.
[24] Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011;29:e443–5.
[25] Cheung LW, Hennessy BT, Li J, et al. High frequency of PI3KCA and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011;1:170–85.
[26] Yeudall WA. p53 mutation in the genesis of metastasis. Subcell Biochem 2014;85:105–17.
[27] Kreahling JM, Foroutan P, Reed D, et al. Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcoma. PLoS One 2013;8:e57523.
[28] Hirai H, Arai T, Okada M, et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010;9:514–22.